Compare Stocks: APTO, SLDB, IPHYF, and CASI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
IPHYF Innate Pharma	$1.65	$1.69	$1.37 ▼ $2.25	$138.32M	0.29	N/A	N/A
SLDB Solid Biosciences	$8.49 +5.6%	$8.38	$3.79 ▼ $11.45	$791.53M	2.36	1.23 million shs	845,970 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	+0.00%	-86.35%
IPHYF Innate Pharma	0.00%	0.00%	0.00%	+10.00%	+25.95%
SLDB Solid Biosciences	+5.60%	+6.39%	-15.02%	+16.94%	+20.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
IPHYF Innate Pharma	$1.65	$1.69	$1.37 ▼ $2.25	$138.32M	0.29	N/A	N/A
SLDB Solid Biosciences	$8.49 +5.6%	$8.38	$3.79 ▼ $11.45	$791.53M	2.36	1.23 million shs	845,970 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	+0.00%	-86.35%
IPHYF Innate Pharma	0.00%	0.00%	0.00%	+10.00%	+25.95%
SLDB Solid Biosciences	+5.60%	+6.39%	-15.02%	+16.94%	+20.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	0.00	N/A	N/A	N/A
CASI CASI Pharmaceuticals	2.00	Hold	$4.00	1,827.71% Upside
IPHYF Innate Pharma	0.00	N/A	N/A	N/A
SLDB Solid Biosciences	2.91	Moderate Buy	$17.11	101.54% Upside

Current Analyst Ratings Breakdown

Latest APTO, SLDB, IPHYF, and CASI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/3/2026	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00
5/13/2026	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$17.00 ➝ $18.00
5/13/2026	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$17.00 ➝ $16.00

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
CASI CASI Pharmaceuticals	$26.85M	0.10	N/A	N/A	$0.12 per share	1.73
IPHYF Innate Pharma	$10.19M	13.57	N/A	N/A	($0.29) per share	-5.69
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$2.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
CASI CASI Pharmaceuticals	-$39.26M	-$3.01	N/A	N/A	N/A	-183.93%	N/A	-131.54%	N/A
IPHYF Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/17/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.95	N/A	N/A	N/A	N/A	-73.42%	-61.13%	8/11/2026 (Estimated)

Latest APTO, SLDB, IPHYF, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	SLDB Solid Biosciences	-$0.43	N/A	N/A	N/A	N/A	N/A
5/12/2026	Q1 2026	SLDB Solid Biosciences	-$0.40	-$0.52	-$0.12	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IPHYF Innate Pharma	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
CASI CASI Pharmaceuticals	N/A	0.30	0.24
IPHYF Innate Pharma	N/A	1.27	1.27
SLDB Solid Biosciences	N/A	13.10	13.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
CASI CASI Pharmaceuticals	22.23%
IPHYF Innate Pharma	N/A
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
CASI CASI Pharmaceuticals	21.24%
IPHYF Innate Pharma	31.89%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
IPHYF Innate Pharma	179	83.83 million	57.10 million	Not Optionable
SLDB Solid Biosciences	100	98.45 million	95.83 million	Optionable

APTO, SLDB, IPHYF, and CASI Headlines

Recent News About These Companies

Stempoint Capital LP Purchases New Position in Solid Biosciences Inc. $SLDB

July 30 at 6:08 AM | marketbeat.com

Solid Biosciences Inc. $SLDB Holdings Boosted by Redmile Group LLC

July 29 at 5:59 AM | marketbeat.com

Solid Biosciences Inc. $SLDB Shares Purchased by Ally Bridge Group NY LLC

July 29 at 3:11 AM | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 26, 2026 | americanbankingnews.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Analysts

July 26, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Trading Down 9% - Here's What Happened

July 10, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Solid Biosciences to Participate at Upcoming Investor Conferences

June 1, 2026 | globenewswire.com

J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

May 24, 2026 | theglobeandmail.com

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

May 20, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)

May 14, 2026 | theglobeandmail.com

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 12, 2026 | globenewswire.com

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

May 7, 2026 | globenewswire.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026 | globenewswire.com

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

April 30, 2026 | globenewswire.com

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

April 28, 2026 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB)

April 17, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APTO, SLDB, IPHYF, and CASI Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

CASI Pharmaceuticals NASDAQ:CASI

$0.21 0.00 (0.00%)

As of 07/29/2026

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Innate Pharma OTCMKTS:IPHYF

$1.65 0.00 (0.00%)

As of 07/29/2026

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Solid Biosciences NASDAQ:SLDB

$8.49 +0.45 (+5.60%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$8.47 -0.02 (-0.27%)

As of 07/30/2026 07:59 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, SLDB, IPHYF, and CASI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, SLDB, IPHYF, and CASI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, SLDB, IPHYF, and CASI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APTO, SLDB, IPHYF, and CASI Company Descriptions

Aptose Biosciences NASDAQ:APTO

CASI Pharmaceuticals NASDAQ:CASI

Innate Pharma OTCMKTS:IPHYF

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, SLDB, IPHYF, and CASI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, SLDB, IPHYF, and CASI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, SLDB, IPHYF, and CASI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APTO, SLDB, IPHYF, and CASI Company Descriptions

Aptose Biosciences NASDAQ:APTO

CASI Pharmaceuticals NASDAQ:CASI

Innate Pharma OTCMKTS:IPHYF

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools